美国他汀类药物用于心血管疾病二级预防仍不理想
本研究基于2008至2016年美国医疗支出面板调查数据,分析动脉粥样硬化性心血管疾病(ASCVD)患者他汀类药物二级预防的使用趋势。女性(OR 0.65)和西班牙裔(OR 0.69)使用他汀的 odds 较低。
要点
- 2008至2016年ASCVD患者他汀使用率无改善。
- 女性与西班牙裔他汀使用 odds 显著低于对照。
核心结论
- 2013年ACC/AHA二级预防指南发布及通用他汀可及后,美国他汀二级预防使用率未见增加。
- 性别和种族差异在ASCVD治疗中持续存在。
研究设计与样本
- 基于医疗支出面板调查(MEPS)2008至2016年数据的趋势分析。
- 采用多变量逻辑回归分析2014至2016年社会人口学特征与他汀使用的关联。
主要发现
- 2008至2016年有ASCVD病史者他汀使用率保持不变。
- 年龄增长和高胆固醇诊断(OR 6.22;P < .001)与他汀使用 odds 升高相关。
- 女性(OR 0.65;P < .001)和西班牙裔(OR 0.69;P = .011)与他汀使用 odds 降低相关。
关键数值与推荐
- 2013年ACC/AHA指南发布后3年(2014至2016年)多变量分析显示女性OR 0.65(P < .001)、西班牙裔OR 0.69(P = .011)。
- 高胆固醇诊断OR 6.22(P < .001)与他汀使用正相关。
临床怎么用
- 全科医生应主动评估ASCVD患者他汀使用情况,尤其关注女性和西班牙裔患者。
- 对未使用他汀的ASCVD患者应排查原因并促进指南推荐的他汀治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of mortality in the United States. The purpose of this study is to examine the rates of statin use for secondary prevention of ASCVD events in the United States over the last decade and determine whether disparities in the treatment of ASCVD still persist among women and racial/ethnic minorities. METHODS: We conducted a trend analysis using data from 2008 through 2016 to describe age-adjusted trends in the use of statins for secondary prevention using the Medical Expenditure Panel Survey. We also conducted a multivariable logistic regression analysis to determine whether sociodemographic characteristics are associated with statin use during the 3 years that followed the publication of the 2013 American College of Cardiology/American Heart Association (ACC/AHA) guideline (2014 through 2016). RESULTS: The prevalence of statin use among those with a history of ASCVD remained unchanged from 2008 through 2016. In 2014 to 2016, more than 40% of those aged 40 years and older with a history of ASCVD did not use statins, corresponding to approximately 9.5 million Americans. Increasing age and having been diagnosed with high cholesterol (odds ratio [OR], 6.22; P < .001) were associated with higher odds of statin use while being female (OR, 0.65; P < .001) or Hispanic (OR, 0.69; P = .011) were associated with lower odds of statin use. CONCLUSIONS: Our study found there was no increase in the national rates of statin use following the ACC/AHA 2013 secondary prevention guideline and the availability of generic statins. Significant gender and ethnic disparities in ASCVD treatment remained in the United States.
引用
- Ngo-Metzger Q, Zuvekas S, Shafer P, et al. Statin Use in the U.S. for Secondary Prevention of Cardiovascular Disease Remains Suboptimal. J Am Board Fam Med. 2019. PMID: 31704749. doi:10.3122/jabfm.2019.06.180313
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。